💊 医薬品 A-Z 🧬 標的 🛠 ツール 📚 ガイド
全医薬品 薬物分類 治療領域 副作用
ガイド 用語集 年表
比較 薬物の体内の旅 薬物ファミリー
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Rivaroxaban

CHEMBL198362 Phase 4 承認済み Small molecule
Half-Life
5-9 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
435.9 g/mol
LogP
2.5
Phase
4

A direct oral anticoagulant that inhibits Factor Xa, used to prevent and treat blood clots in conditions such as atrial fibrillation, deep vein thrombosis, and pulmonary embolism. Unlike warfarin, it requires no routine blood monitoring and has fewer food and drug interactions.

分子量

435.8820 g/mol

LogP

2.50

TPSA

116.00 Ų

リピンスキーの五則

適合

治療領域

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Cardiovascular Disease Non-Small Cell Lung Cancer Rheumatoid Arthritis Chronic Obstructive Pulmonary Disease Migraine Infectious Disease Systemic Lupus Erythematosus Chronic Kidney Disease Stroke Deep Vein Thrombosis / Pulmonary Embolism Obesity Lymphoma Type 2 Diabetes Hypertension Breast Cancer Heart Failure Atrial Fibrillation Prostate Cancer Colorectal Cancer Leukemia

薬物分類

B — B - Blood and Blood Forming Organs

作用機序

Direct Factor Xa inhibitor.

Pharmacokinetics (PK)

Half-Life 5-9 hours

Pharmacodynamics (PD)

機序

Direct Factor Xa inhibitor.

2D構造

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1

                

                

                
                

                    
InChI

                    
InChI=1S/C19H18ClN3O5S/c20-16-6-5-15(29-16)18(25)21-9-14-10-23(19(26)28-14)13-3-1-12(2-4-13)22-7-8-27-11-17(22)24/h1-6,14H,7-11H2,(H,21,25)/t14-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C19H18ClN3O5S

                    

                    
                    

                        
HBD / HBA

                        
1 / 6

                    

                    
                    

                        
回転可能結合数

                        
5

                    

                    
                    
                    

                        
重原子数

                        
29

                    

                    
                

            


            
            

                
                

                    
                    

                        

                            F10 (Factor Xa)
                            Inhibitor
                        

                        
                        Primary Target
                        
                    

                    
                    

                        

                            CYP3A4 (Cytochrome P450 3A4)
                            Substrate
                        

                        
                    

                    
                    

                        

                            ABCB1 (P-glycoprotein)
                            Substrate
                        

                        
                    

                    
                

                
            


            
            

                
                

                    
                    
                        

                            

  
  Major


                            
                                Rivaroxaban + Clopidogrel
                            
                        

                        
                        
Combining rivaroxaban with clopidogrel substantially increases bleeding risk through simultaneous inhibition of factor Xa and platelet P2Y12 receptors.

                        
                    
                    
                    
                        

                            

  
  Major


                            
                                Rivaroxaban + Fluconazole
                            
                        

                        
                        
Fluconazole markedly increases rivaroxaban exposure through dual inhibition of CYP3A4 and P-glycoprotein, substantially elevating bleeding risk.

                        
                    
                    
                    
                        

                            

  
  Major


                            
                                Rivaroxaban + Cyclosporine
                            
                        

                        
                        
Cyclosporine, a strong dual inhibitor of CYP3A4 and P-glycoprotein, substantially increases rivaroxaban exposure and bleeding risk.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Rivaroxaban + Aspirin
                            
                        

                        
                        
Adding aspirin to rivaroxaban increases bleeding risk through additive antithrombotic effects; some indications (COMPASS trial) use this combination with careful patient selection.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
よくある質問

                

                    
                    

                        
                        

                            
A direct oral anticoagulant that inhibits Factor Xa, used to prevent and treat blood clots in conditions such as atrial fibrillation, deep vein thrombosis, and pulmonary embolism. Unlike warfarin, it requires no routine blood monitoring and has fewer food and drug interactions.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Direct Factor Xa inhibitor.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Rivaroxaban: Half-life: 5-9 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Rivaroxaban is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            
            

                
                
                    ADME Journey →
                
                
                
            

            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Warfarin
                            Small molecule
                        
                        
                        
                            Clopidogrel
                            Small molecule
                        
                        
                        
                            Apixaban
                            Small molecule
                        
                        
                        
                            Dabigatran
                            Small molecule
                        
                        
                    

                

                

                
                
                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL198362.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 9875401.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
医学的免責事項

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.